Skip to main content
Erschienen in: Endocrine 2/2020

02.03.2020 | Original Article

Long-term real-life outcomes in a georrefered cohort of acromegalic patients in Brazil

verfasst von: Lara Benigno Porto, José Wilson Corrêa Rosa, João Willy Corrêa Rosa, Luiz Augusto Casulari, Ivan Ricardo Zimmermann, Luciana Ansaneli Naves

Erschienen in: Endocrine | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Epidemiological data on acromegaly therapeutic outcomes in real-life conditions are scarce in Brazil. Information on the geographical accessibility to the dispensation of medicines and its impact on biochemical control is also poorly known. We aimed to describe the clinical outcomes of long-term therapy in patients with acromegaly at a referral medical centre in Brazil and to perform a spatial analysis of patients according to the distance from home to the drug-dispensing pharmacies aiming to evaluate its impact on biochemical control.

Methods

Global retrospective data analysis of 111 patients followed at the University Hospital of Brasília from January 1980 to March 2015 was performed, as well as a separate review of 17 new cases operated on from April 2015 to June 2019 according to surgery results. Spatial analysis of patients under pharmacological treatment applying Geographic Information System (GIS) software (ArcGIS, ESRI, Redlands, CA) was performed.

Results

Considering surgery alone, the cure rate was 23% from 1980 to 2015 and 29.4% from 2015 to 2019. In the long-term follow-up of the 111 patients from 1980 to 2015, 25.2% (n = 29) were cured, 40.6% (n = 44) presented controlled disease and 34.2% (n = 38) were biochemically uncontrolled after a period of follow-up of 8.9 ± 6.4 years. Biochemical control obtained in patients on pharmacological treatment (n = 76) was 58% (n = 44) after 5.8 ± 3.8 years. The distance from home to the drug-dispensing pharmacy did not influence biochemical control (p = 0.7616).

Conclusions

Most patients presented with disease under control. No evidence on the effect of the distance between home and drug-dispensing pharmacies on biochemical control was obtained.
Literatur
1.
Zurück zum Zitat A. Ben-Shlomo, S. Melmed, Acromegaly. Endocrinol. Metab. Clin. North Am. 37(1), 101–122 (2008) A. Ben-Shlomo, S. Melmed, Acromegaly. Endocrinol. Metab. Clin. North Am. 37(1), 101–122 (2008)
2.
Zurück zum Zitat P. Chanson, S. Salenave, P. Kamenicky, L. Cazabat, J. Young, Acromegaly. Best. Pr. Res Clin. Endocrinol. Metab. 23, 555–574 (2009)CrossRef P. Chanson, S. Salenave, P. Kamenicky, L. Cazabat, J. Young, Acromegaly. Best. Pr. Res Clin. Endocrinol. Metab. 23, 555–574 (2009)CrossRef
3.
Zurück zum Zitat A. Abreu, A.P. Tovar, R. Castellanos, A. Valenzuela, C.M.G. Giraldo, A.C. Pinedo et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary 19, 448–457 (2016)CrossRef A. Abreu, A.P. Tovar, R. Castellanos, A. Valenzuela, C.M.G. Giraldo, A.C. Pinedo et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary 19, 448–457 (2016)CrossRef
4.
Zurück zum Zitat A.F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M.A. Tichomirowa, A. Beckers, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91, 4769–4775 (2006)CrossRef A.F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M.A. Tichomirowa, A. Beckers, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91, 4769–4775 (2006)CrossRef
5.
Zurück zum Zitat H.J. Schneider, C. Sievers, B. Saller, H.U. Wittchen, G.K. Stalla, High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin. Endocrinol. (Oxf.) 69, 432–435 (2008)CrossRef H.J. Schneider, C. Sievers, B. Saller, H.U. Wittchen, G.K. Stalla, High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin. Endocrinol. (Oxf.) 69, 432–435 (2008)CrossRef
7.
Zurück zum Zitat S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg et al. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509–1517 (2009) S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg et al. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509–1517 (2009)
8.
Zurück zum Zitat L. Katznelson, E.R. Laws, S. Melmed, M.E. Molitch, M.H. Murad, A. Utz et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3933–3951 (2014)CrossRef L. Katznelson, E.R. Laws, S. Melmed, M.E. Molitch, M.H. Murad, A. Utz et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3933–3951 (2014)CrossRef
9.
Zurück zum Zitat L.V. Neto, J. Abucham, A.L. Araujo, L. Boguszewski, D. Bronstein, M. Czepielewski, M. Recomendações, do Departamento de Neutoendrocrinologia da Sociedade Brasileira de Endocrinologia e Metabologia para o diagnóstico e tratamento de acromegalia no Brasil. Arq Bras Endocrinol. Metab. 55, 91–105 (2011)CrossRef L.V. Neto, J. Abucham, A.L. Araujo, L. Boguszewski, D. Bronstein, M. Czepielewski, M. Recomendações, do Departamento de Neutoendrocrinologia da Sociedade Brasileira de Endocrinologia e Metabologia para o diagnóstico e tratamento de acromegalia no Brasil. Arq Bras Endocrinol. Metab. 55, 91–105 (2011)CrossRef
10.
Zurück zum Zitat A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141–3148 (2010)CrossRef A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141–3148 (2010)CrossRef
11.
Zurück zum Zitat F.F. Casanueva, J.A.H. Wass, C.J. Strasburger, D.R. Clemmons, A. Giustina, Expert consensus document: statement on acromegaly therapeutics outcomes. Nat. Rev. Endocrinol. 14(9), 552–561 (2018)CrossRef F.F. Casanueva, J.A.H. Wass, C.J. Strasburger, D.R. Clemmons, A. Giustina, Expert consensus document: statement on acromegaly therapeutics outcomes. Nat. Rev. Endocrinol. 14(9), 552–561 (2018)CrossRef
12.
Zurück zum Zitat M. Buchfelder, S.-M. Schlaffer, The surgical treatment of acromegaly. Pituitary 20, 76–83 (2017)CrossRef M. Buchfelder, S.-M. Schlaffer, The surgical treatment of acromegaly. Pituitary 20, 76–83 (2017)CrossRef
13.
Zurück zum Zitat C. Schöfl, H. Franz, M. Grussendorf, J. Honegger, C. Jaursch-Hancke, B. Mayr et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German acromegaly register. Eur. J. Endocrinol. 168, 39–47 (2013)CrossRef C. Schöfl, H. Franz, M. Grussendorf, J. Honegger, C. Jaursch-Hancke, B. Mayr et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German acromegaly register. Eur. J. Endocrinol. 168, 39–47 (2013)CrossRef
14.
Zurück zum Zitat Institute of Medicine. Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research. (National Academies Press Washington, DC, USA). U.S. Department of Health and Human Services, HIPAA Regul §164514 Institute of Medicine. Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research. (National Academies Press Washington, DC, USA). U.S. Department of Health and Human Services, HIPAA Regul §164514
15.
Zurück zum Zitat M.P. Armstrong, G. Rushton, D.L. Zimmerman, Geographically masking health data to preserve confidentiality. Stat. Med. 18, 497–525 (1999)CrossRef M.P. Armstrong, G. Rushton, D.L. Zimmerman, Geographically masking health data to preserve confidentiality. Stat. Med. 18, 497–525 (1999)CrossRef
16.
Zurück zum Zitat D.I. Gregorio, L.M. DeChello, H. Samociuk, M. Kulldorff, Lumping or splitting: seeking the preferred areal unit for health geography studies. Int. J. Health Geogr. 4(1), 6 (2005) D.I. Gregorio, L.M. DeChello, H. Samociuk, M. Kulldorff, Lumping or splitting: seeking the preferred areal unit for health geography studies. Int. J. Health Geogr. 4(1), 6 (2005)
17.
Zurück zum Zitat A. Ben-Shlomo, M.C. Sheppard, J.M. Stephens, S. Pulgar, S. Melmed, Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14, 284–294 (2011)CrossRef A. Ben-Shlomo, M.C. Sheppard, J.M. Stephens, S. Pulgar, S. Melmed, Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14, 284–294 (2011)CrossRef
18.
Zurück zum Zitat L.B. Porto, I.R. Zimmermann, L.A. Naves, Economics of acromegaly treatment in Brazil: a budget impact analysis of pituitary surgery compared with long‑term octreotide LAR. Pharmacoecon Open 3(2), 247–254 (2019)CrossRef L.B. Porto, I.R. Zimmermann, L.A. Naves, Economics of acromegaly treatment in Brazil: a budget impact analysis of pituitary surgery compared with long‑term octreotide LAR. Pharmacoecon Open 3(2), 247–254 (2019)CrossRef
22.
Zurück zum Zitat A. Mestrón, S.M. Webb, R. Astorga, P. Benito, M. Catalá, S. Gaztambide et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur. J. Endocrinol. 151(4), 439–446 (2004) A. Mestrón, S.M. Webb, R. Astorga, P. Benito, M. Catalá, S. Gaztambide et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur. J. Endocrinol. 151(4), 439–446 (2004)
23.
Zurück zum Zitat G. Sesmilo, S. Gaztambide, E. Venegas, A. Picó, C. Del Pozo, C. Blanco et al. Changes in acromegaly treatment over four decades in Spain: analysis of the spanish acromegaly registry (REA). Pituitary 16, 115–121 (2013)CrossRef G. Sesmilo, S. Gaztambide, E. Venegas, A. Picó, C. Del Pozo, C. Blanco et al. Changes in acromegaly treatment over four decades in Spain: analysis of the spanish acromegaly registry (REA). Pituitary 16, 115–121 (2013)CrossRef
24.
Zurück zum Zitat M. Arosio, G. Reimondo, E. Malchiodi, P. Berchialla, A. Borraccino, L. De Marinis et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur. J. Endocrinol. 167, 189–198 (2012)CrossRef M. Arosio, G. Reimondo, E. Malchiodi, P. Berchialla, A. Borraccino, L. De Marinis et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur. J. Endocrinol. 167, 189–198 (2012)CrossRef
25.
Zurück zum Zitat P. Petrossians, A.F. Daly, E. Natchev, L. Maione, K. Blijdorp, M. Sahnoun-Fathallah et al. Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) database. Endocr. Relat. Cancer 24, 505–518 (2017)CrossRef P. Petrossians, A.F. Daly, E. Natchev, L. Maione, K. Blijdorp, M. Sahnoun-Fathallah et al. Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) database. Endocr. Relat. Cancer 24, 505–518 (2017)CrossRef
26.
Zurück zum Zitat S. Vallette, O. Serri, Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly? Pituitary 13, 311–314 (2010)CrossRef S. Vallette, O. Serri, Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly? Pituitary 13, 311–314 (2010)CrossRef
27.
Zurück zum Zitat J. Roemmler, M. Bidlingmaier, J. Schopohl, Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant. Pituitary 13, 89–93 (2010)CrossRef J. Roemmler, M. Bidlingmaier, J. Schopohl, Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant. Pituitary 13, 89–93 (2010)CrossRef
28.
Zurück zum Zitat L.A. Naves, L.B. Porto, J.W.C. Rosa, L.A. Casulari, J.W.C. Rosa, Geographical information system (GIS) as a new tool to evaluate epidemiology based on spatial analysis and clinical outcomes in acromegaly. Pituitary 18(1), 8–15 (2015)CrossRef L.A. Naves, L.B. Porto, J.W.C. Rosa, L.A. Casulari, J.W.C. Rosa, Geographical information system (GIS) as a new tool to evaluate epidemiology based on spatial analysis and clinical outcomes in acromegaly. Pituitary 18(1), 8–15 (2015)CrossRef
29.
Zurück zum Zitat P. Petrossians, M.A. Tichomirowa, A. Stevenaert, D. Martin, A.F. Daly, A. Beckers, The Liege Acromegaly Survey (LAS): a new software tool for the study of acromegaly. Ann Endocrinol. (Paris) 73, 190–201 (2012)CrossRef P. Petrossians, M.A. Tichomirowa, A. Stevenaert, D. Martin, A.F. Daly, A. Beckers, The Liege Acromegaly Survey (LAS): a new software tool for the study of acromegaly. Ann Endocrinol. (Paris) 73, 190–201 (2012)CrossRef
30.
Zurück zum Zitat P. Nomikos, M. Buchfelder, R. Fahlbusch, The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical “cure”. Eur. J. Endocrinol. 152, 379–387 (2005)CrossRef P. Nomikos, M. Buchfelder, R. Fahlbusch, The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical “cure”. Eur. J. Endocrinol. 152, 379–387 (2005)CrossRef
31.
Zurück zum Zitat I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667–674 (2004)CrossRef I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667–674 (2004)CrossRef
32.
Zurück zum Zitat M. Bex, R. Abs, G. T’Sjoen, J. Mockel, B. Velkeniers, K. Muermans et al. AcroBel—the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157, 399–409 (2007)CrossRef M. Bex, R. Abs, G. T’Sjoen, J. Mockel, B. Velkeniers, K. Muermans et al. AcroBel—the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157, 399–409 (2007)CrossRef
33.
Zurück zum Zitat O. Kwon, Y.D. Song, S.Y. Kim, E.J. Lee, Nationwide survey of acromegaly in South Korea. Clin. Endocrinol. (Oxf.) 78, 577–585 (2013)CrossRef O. Kwon, Y.D. Song, S.Y. Kim, E.J. Lee, Nationwide survey of acromegaly in South Korea. Clin. Endocrinol. (Oxf.) 78, 577–585 (2013)CrossRef
34.
Zurück zum Zitat R. Kauppinen-Mäkelin, T. Sane, A. Reunanen, M.J. Välimäki, L. Niskanen, H. Markkanen et al. A nationwide survey of mortality in acromegaly. J. Clin. Endocrinol. Metab. 90, 4081–4086 (2005)CrossRef R. Kauppinen-Mäkelin, T. Sane, A. Reunanen, M.J. Välimäki, L. Niskanen, H. Markkanen et al. A nationwide survey of mortality in acromegaly. J. Clin. Endocrinol. Metab. 90, 4081–4086 (2005)CrossRef
35.
Zurück zum Zitat L.A. Portocarrero-Ortiz, A. Vergara-Lopez, M. Vidrio-Velazquez, A.M. Uribe-Diaz, A. García-Dominguez, A.A. Reza-Albarrán et al. The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J. Clin. Endocrinol. Metab. 101, 3997–4004 (2016)CrossRef L.A. Portocarrero-Ortiz, A. Vergara-Lopez, M. Vidrio-Velazquez, A.M. Uribe-Diaz, A. García-Dominguez, A.A. Reza-Albarrán et al. The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J. Clin. Endocrinol. Metab. 101, 3997–4004 (2016)CrossRef
36.
Zurück zum Zitat A.L. Barkan, Radiotherapy in acromegaly: the argument against. Clin. Endocrinol. (Oxf.) 58, 132–135 (2003)CrossRef A.L. Barkan, Radiotherapy in acromegaly: the argument against. Clin. Endocrinol. (Oxf.) 58, 132–135 (2003)CrossRef
37.
Zurück zum Zitat P.U. Freda, L. Katznelson, A.J. Van Der Lely, C.M. Reyes, S. Zhao, D. Rabinowitz, Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 4465–4473 (2005)CrossRef P.U. Freda, L. Katznelson, A.J. Van Der Lely, C.M. Reyes, S. Zhao, D. Rabinowitz, Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 4465–4473 (2005)CrossRef
38.
Zurück zum Zitat L. Sandret, P. Maison, P. Chanson, Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 1327–1335 (2011)CrossRef L. Sandret, P. Maison, P. Chanson, Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 1327–1335 (2011)CrossRef
39.
Zurück zum Zitat A. Colao, R.S. Auriemma, R. Pivonello, L. Kasuki, M.R. Gadelha, Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19, 235–247 (2016)CrossRef A. Colao, R.S. Auriemma, R. Pivonello, L. Kasuki, M.R. Gadelha, Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19, 235–247 (2016)CrossRef
40.
Zurück zum Zitat R.S. Jallad, N.R. Musolino, S. Kodaira, V.A. Cescato, M.D. Bronstein, Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin. Endocrinol. (Oxf.) 67, 310–315 (2007)CrossRef R.S. Jallad, N.R. Musolino, S. Kodaira, V.A. Cescato, M.D. Bronstein, Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin. Endocrinol. (Oxf.) 67, 310–315 (2007)CrossRef
41.
Zurück zum Zitat P. Petrossians, L. Borges-Martins, C. Espinoza, A. Daly, D. Betea, H. Valdes-Socin et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur. J. Endocrinol. 152, 61–66 (2005)CrossRef P. Petrossians, L. Borges-Martins, C. Espinoza, A. Daly, D. Betea, H. Valdes-Socin et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur. J. Endocrinol. 152, 61–66 (2005)CrossRef
42.
Zurück zum Zitat N. Karavitaki, H.E. Turner, C.B.T. Adams, S. Cudlip, J.V. Byrne, V. Fazal-Sanderson et al. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin. Endocrinol. (Oxf.) 68, 970–975 (2008)CrossRef N. Karavitaki, H.E. Turner, C.B.T. Adams, S. Cudlip, J.V. Byrne, V. Fazal-Sanderson et al. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin. Endocrinol. (Oxf.) 68, 970–975 (2008)CrossRef
43.
Zurück zum Zitat C.L. Boguszewski, M.K.P Huayllas, L. Vilar, L.A. Naves, A.R. Junior, B.S. Soares et al. Brazilian multicenter study on pegvisomant treatment in acromegaly. Arch. Endocrinol. Metab. 63(4), 328–336 (2019) C.L. Boguszewski, M.K.P Huayllas, L. Vilar, L.A. Naves, A.R. Junior, B.S. Soares et al. Brazilian multicenter study on pegvisomant treatment in acromegaly. Arch. Endocrinol. Metab. 63(4), 328–336 (2019)
46.
Zurück zum Zitat M. Calovi, Using a GIS to support the spatial reorganization of outpatient care services delivery in Italy. BMC Health Serv. Res. 4, 1–16 (2018) M. Calovi, Using a GIS to support the spatial reorganization of outpatient care services delivery in Italy. BMC Health Serv. Res. 4, 1–16 (2018)
47.
Zurück zum Zitat R.S. Kirby, E. Delmelle, J.M. Eberth, Advances in spatial epidemiology and geographic information systems. Ann. Epidemiol. 27(1), 1–9 (2017)CrossRef R.S. Kirby, E. Delmelle, J.M. Eberth, Advances in spatial epidemiology and geographic information systems. Ann. Epidemiol. 27(1), 1–9 (2017)CrossRef
Metadaten
Titel
Long-term real-life outcomes in a georrefered cohort of acromegalic patients in Brazil
verfasst von
Lara Benigno Porto
José Wilson Corrêa Rosa
João Willy Corrêa Rosa
Luiz Augusto Casulari
Ivan Ricardo Zimmermann
Luciana Ansaneli Naves
Publikationsdatum
02.03.2020
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02240-5

Weitere Artikel der Ausgabe 2/2020

Endocrine 2/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.